ProfileGDS5678 / 1422451_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 93% 93% 91% 93% 93% 91% 93% 93% 92% 92% 92% 93% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.6748492
GSM967853U87-EV human glioblastoma xenograft - Control 27.9072893
GSM967854U87-EV human glioblastoma xenograft - Control 37.995593
GSM967855U87-EV human glioblastoma xenograft - Control 47.6497591
GSM967856U87-EV human glioblastoma xenograft - Control 58.019593
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.5587393
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.2228691
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.778193
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.7808993
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.6815992
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.6342792
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6417892
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.9216193
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8898293